Listen on the go
CORRECT!
Next question
touchCARDIO touchCARDIO

Start Learning

Touch Loading image
JOURNALS
Start Learning
3 Questions with Dr Salik Ur Rehman Iqbal: touchCARDIO Future Leader 2025
JOURNALS
Start Learning
Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis
JOURNALS
Start Learning
EuroPCR 2024: Key Highlights
touchCONGRESS
Start Learning
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
CE/CME ACCREDITED
Monoclonal Antibody Targeting ANGPTL4 Shows Lipid-Lowering Effects in High-Risk Cardiovascular Patients
JOURNALS
Start Learning
Monoclonal Antibody Targeting ANGPTL4 Shows Lipid-Lowering Effects in High-Risk Cardiovascular Patients
3d rendered medical illustration of the human heart highlighted in the chest
JOURNALS
Start Learning
Coronary Dissection – Back to the Future – Finding Good in the Bad!
JOURNALS
Start Learning
Heart International achieves new Impact Factor milestone of 1.9 in 2024 Journal Citation Reports
CONFERENCE HUB
Start Learning
Biomarkers for improved risk prediction and biological insights in patients with atrial fibrillation
touchDATA POINT
Start Learning
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolemia
Sponsored content
Ifetroban improves heart function in DMD: Promising phase II trial results from FIGHT
JOURNALS
Start Learning
Ifetroban improves heart function in Duchenne muscular dystrophy: Promising phase II trial results from FIGHT

to view Favourites, Keep Notes and Track CME Credits

Favourites
Obituary – Richard Heuser
View
Radial Artery Thrombosis and Associated Risk Factors in Patients Undergoing Radial Coronary Angiography
View
Advancing Atrial Fibrillation Treatment: Exploring Novel Methods in the Ground-BrEAking Electroporation-based inTervention for Atrial Fibrillation Trial
View
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolemia
View
Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies
View
Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies
View
The next frontier in managing obesity with or without T2D: The role of novel combinations
View
FOREWORD – HEART INTERNATIONAL – VOLUME 18 ISSUE 1 – 2024
View
ESC 2024 preview: Personalising cardiovascular care
View
Greatest Hits of 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup